You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK solid tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Paris, France
  • +1 more
Sep 27, 2022

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

Not yet recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Providence, Rhode Island
    Rhode Island Hospital, Brown University
Mar 2, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

ALK Fusion-positive Solid or CNS Tumors Trial in Worldwide (Alectinib)

Recruiting
  • ALK Fusion-positive Solid or CNS Tumors
  • New York, New York
  • +17 more
Jul 25, 2022

Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)

Active, not recruiting
  • Hematologic Cancers
  • +2 more
  • Villejuif, Ile De France, France
    Gustave Roussy
Sep 5, 2022

Tumors, Colorectal Tumors, Melanoma Trial in United States (Alectinib)

Terminated
  • Neoplasms
  • +27 more
  • Culver City, California
  • +28 more
Jul 25, 2022

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Trial in Shanghai (SIM1803-1A)

Recruiting
  • Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
  • Shanghai, China
    Shanghai Chest Hospital
Jan 11, 2021

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

Recruiting
  • Locally Advanced Solid Tumors
  • +3 more
  • Oral repotrectinib (TPX-0005)
  • Los Angeles, California
  • +27 more
Aug 9, 2022

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Tumor, Advanced ALK+ or ROS1+Solid Tumors Trial in Worldwide (Midazolam,

Completed
  • Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
  • Paris, Ile-de-france, France
  • +13 more
May 19, 2021

Advanced Solid Tumors, NSCLC Trial in United States (Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib))

Completed
  • Advanced Solid Tumors
  • Non-small Cell Lung Cancer
  • Phase I: X-396 (ensartinib)
  • Phase II: X-396 (ensartinib)
  • Duarte, California
  • +13 more
Oct 4, 2021

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Korea, Republic of, United States (Entrectinib)

Completed
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Orange, California
  • +9 more
Jun 7, 2021

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Patients With Advanced Solid Tumors Trial in Madrid (PM534)

Recruiting
  • Patients With Advanced Solid Tumors
  • Madrid, Spain
  • +1 more
Apr 18, 2023

Advanced Solid Tumor Trial in Changsha (IBI363)

Not yet recruiting
  • Advanced Solid Tumor
  • Changsha, Hunan, China
    Yongchang Zhang
Oct 12, 2023

NUT Midline Carcinoma, Triple Negative Breast Cancer, NSCLC With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Trial

Completed
Has Results
  • NUT Midline Carcinoma
  • +5 more
  • (no location specified)
Jan 7, 2021

Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors Trial (INCA33890)

Not yet recruiting
  • Solid Tumors
  • +2 more
  • (no location specified)
Apr 26, 2023

Advanced Solid Tumors Trial (AMG 355, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Nov 9, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

NHWD-870 in Advanced Solid Tumors or Lymphomas Carrying NUT

Recruiting
  • Advanced Solid Tumors or Lymphomas
  • Changsha, Hunan, China
    Hunan Provincal Tumor Hospital
Oct 5, 2023

HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor

Not yet recruiting
  • HER2-expressing Advanced Solid Tumors
  • SHR-A1811 combined with Pyrotinib.
  • SHR-A1811 combined with other antitumor therapies
  • (no location specified)
Aug 28, 2023

Advanced Solid Tumors Trial (QL1706H)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Sep 18, 2023

Advanced Solid Tumors With Neuroendocrine Differentiation Trial (surufatinib?serplulimab)

Not yet recruiting
  • Advanced Solid Tumors With Neuroendocrine Differentiation
  • (no location specified)
Nov 27, 2023

Advanced Solid Cancer Trial (ORB-011)

Not yet recruiting
  • Advanced Solid Cancer
  • (no location specified)
Jul 14, 2023

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

Solid Tumors Trial (IBR854 Cell Injection)

Not yet recruiting
  • Solid Tumors
  • IBR854 Cell Injection
  • (no location specified)
Aug 14, 2023